SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF RECOMBINANT HUMAN COAGULATION FACTOR VIIA FOR INJECTION

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the enrollment of all patients in Phase III clinical trial of "TQG203" (Recombinant Human Coagulation Factor VIIa for Injection), a biologic product developed by the Group, for the on-demand treatment of haemophilia with inhibitors has been completed. The Group expects to submit the application for pre-NDA (New Drug Application) communication to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China in the second quarter of 2023 at the earliest. TQG203 is expected to be the first domestically manufactured Recombinant Human Coagulation Factor VIIa product to be approved.

Haemophilia is an X-chromosome linked recessive hereditary hemorrhagic disorder, mainly classified into haemophilia A and haemophilia B, with a deficiency of coagulation factor VIII and coagulation factor IX respectively. The clinical manifestations are mainly spontaneous, unstoppable bleeding after minor injury or severe bleeding after trauma or surgery. Its treatment includes replacement therapy, adjuvant therapy, prophylaxis and haemophilia inhibitor therapy. Replacement therapy by repeated infusions of coagulation factor VIII and coagulation factor IX preparations may lead to endogenous production of corresponding factor inhibitors, increasing the difficulty of treatment and the disability rate of patients.

Recombinant Human Coagulation Factor VIIa for Injection is a complex active coagulant that activates Factor X directly on the activated platelet surface at the site of injury without relying on tissue factor, catalyzes the conversion of prothrombin into a large amount of thrombin, and initiates

platelets and coagulation factors V and VIII at the site of injury, leading to increased fibrin production and thus achieving haemostasis. Phase I clinical studies have demonstrated that TQG203 has similar pharmacokinetics and pharmacodynamics behaviour to the reference drug and has a good safety profile.

Recombinant Human Coagulation Factor VIIa for Injection is another recombinant coagulation factor product for haemophilia that the Group will soon apply for launch after Recombinant Human Coagulation Factor VIII for Injection. Focusing on the unsatisfied clinical needs and the medication for treatment of patient groups with rare disorders, the Group has been making breakthroughs in the research and development of new drugs, and its new drug pipeline has gradually entered the harvest stage.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 9 December 2022

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.